TABLE A-2Total and Avoidable Costs Due to Adverse Events and Redundant Tests

Avoidable Costs (millions)a (95% confidence interval)Percent of Inpatient Costs (%)Total Costs (millions)a (95% confidence interval)Percent of Inpatient Costs (%)
Thromboembolic disease3,090 (1,979–4,466)1.05,041 (3,444–6966)1.7
Hospital-acquired infections5,797 (3,773–8,198)1.98,912 ($5,833–$12,515)3.0
Adverse drug events3,823 (3,067–4,626)1.38,840 (7,442–10,181)2.9
Decubitus ulcers748 (256–1,332)0.3913 (343–1,595)0.3
Other adverse events3,165 (526–7,884)1.18,569 (1,905–18,192)2.7
Redundant labs and radiology tests8,229 (5,015–11,829)2.78,229 (5,015–11,829)2.7
Total potential savings24,858 (20,386–30,673)8.240,503 (31,929–50,464)13.5
a

Costs in 2004 dollars.

From: Appendix A, Workshop Discussion Background Paper

Cover of The Healthcare Imperative
The Healthcare Imperative: Lowering Costs and Improving Outcomes: Workshop Series Summary.
Institute of Medicine (US) Roundtable on Evidence-Based Medicine; Yong PL, Saunders RS, Olsen LA, editors.
Washington (DC): National Academies Press (US); 2010.
Copyright © 2010, National Academy of Sciences.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.